Jagsonpal acquires Wellness Portfolio from Group Pharmaceuticals

Listed Co AcquisitionStrategic Transactions View source PDF Explain this filing

JAGSNPHARM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+8.9%Reaction day

₹226.91

prior close

₹227.90

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-1.5%+10.3% vs market

Pharmaceuticals peers, median of 172sector-1.0%+9.9% vs sector

On the reaction day the stock moved 10.3 pts more than Nifty Microcap 250 and 9.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+5.9

10m

+7.3

15m

+5.3

30m

+2.8

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+8.9-1.5+10.3-1.0+9.9

Next day

+6.5-1.2+7.7-0.8+7.4

+5.8-2.8+8.5-1.8+7.6

+4.1-1.8+5.9-1.4+5.5

+4.6-2.0+6.6-2.5+7.1

+2.5-3.3+5.8-3.1+5.6

+3.3-2.0+5.3-2.8+6.1

15d

-3.9-3.9+0.1-5.8+1.9

-1.3-10.7+9.4-9.7+8.4

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 172Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Jagsonpal Pharmaceuticals signed a Business Transfer Agreement on Sept 23, 2026 to acquire the Wellness Portfolio of Group Pharmaceuticals on a going-concern slump sale basis. Initial consideration is Rs 23.7 crores at closing, plus up to Rs 23 crores linked to FY28 sales, with a total cap of Rs 46.7 crores. The portfolio reported FY26 revenue of Rs 24.6 crores and focuses on women healthcare. Deal is expected to close by Nov 1, 2026 and is not a related party transaction.

Likely market impact

Strengthens women health portfolio and pan-India reach. Likely earnings-accretive but carries integration and execution risk.